Senores Pharmaceuticals Listing Gains :The year 2024 was approaching and a blockbuster listing was given. The stock of pharma company, Sinores Pharmaceuticals, has made a strong entry in the stock market today. This stock was listed on BSE at a price of Rs 594, while its IPO price was Rs 391. In this sense, the stock has made a profit of 52 percent or Rs 203 per share to the investors on listing. This IPO was open from 20 to 24 December 2024 and it received a strong response from investors. There was a craze about it in the gray market also. The size of the IPO was Rs 582.11 crore.
Highest Return 2024: Up to 434% return this year, these stocks including Zomato, Trent, ICICI Bank became toppers in their respective categories.
Subscribed 97.86 times
The IPO of Senores Pharmaceuticals Limited received an overwhelming response from investors. This IPO was subscribed 97.86 times overall. 75% of the IPO was reserved for QIB and it was subscribed a total of 97.84 times. 15% share in the IPO was reserved for NII and it was subscribed a total of 100.35 times. Whereas 10% portion was reserved for retail investors and it was subscribed 93.16 times.
Return in IPO: The secret of high returns, small size IPO made the highest income in 2024, money increased by 100 to 300%
Senores Pharma: How is the outlook?
Brokerage house Anand Rathi says Senores Pharma develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada and the UK. It also provides services in emerging markets. With a presence in 43 countries, the company focuses on critical care injectables, APIs and complex specialty pharmaceutical products.
The company will use the funds from the IPO to set up a new manufacturing facility at its Atlanta site, meet working capital needs, make acquisitions and other strategic efforts.
Investment: Looking for the best option for investment in the year 2025, these 4 themes can brighten your portfolio.
company financials
The company’s revenue and profit were Rs 14.63 crore and Rs 0.99 crore in FY 2022, which increased to Rs 39.02 crore and Rs 8.43 crore in FY 2023. Revenue and profit in FY 2024 have been Rs 217.34 crore and Rs 32.71 crore. Senores Pharma manufactures medicines. According to the data till September 2024, 55 products have been launched for important treatments including antibiotic and anti-fungal treatments.
(Disclaimer: The view or advice on the share is given by the brokerage house. These are not the personal views of Financial Express. There are risks in the market, so take expert opinion before investing.)
